1. Medtech Insight
  2. >>Archive

Coloplast benefits from currency changes

Helped by beneficial currency moves, sales at Danish company Coloplast increased 19% to DKr 1,112 million ($171 million) in the six months to the end of March. At unchanged exchange rates from the previous year, the rise would still have been strong at 14%, due to growth of the core business and the contribution from the acquisition of Amoena. Sales of Amoena were slightly lower than expected in the first six months but the launch of a light-weight breasts prosthesis and an attachable prosthesis promise good sales growth for the rest of the year, the company said.

Helped by beneficial currency moves, sales at Danish company Coloplast increased 19% to DKr 1,112 million ($171 million) in the six months to the end of March. At unchanged exchange rates from the previous year, the rise would still have been strong at 14%, due to growth of the core business and the contribution from the acquisition of Amoena. Sales of Amoena were slightly lower than expected in the first six months but the launch of a light-weight breasts prosthesis and an attachable prosthesis promise good sales growth for the rest of the year, the company said.

Coloplast described the performance of the female stress incontinence device, Contrelle Activgard, on the Danish consumer market as disappointing. In...

Welcome to Medtech Insight

Create an account to read this article

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Study Finds Public Companies Behind Most Recalled AI Devices

 
• By Elizabeth Orr

A Johns Hopkins University study found publicly traded companies are responsible for 90% of recalled AI-powered medical devices. The study attributes this link to lower clinical validation, especially among smaller companies, and advocates for increased clinical trials to enhance device safety.

Reports Put $4B Price Tag On Versius Maker CMR. Will This Change Surgical Robot Valuation?

 
• By Barnaby Pickering

The value proposition of surgical robots is quickly changing. Gone is the focus on benefit to patients; instead cost, operative efficiency and surgeon longevity are the new focal points, making deciphering M&A value much more difficult.

Four-Year Waits, 60-Page NCDs: Consultant Urges Medicare Overhaul

 
• By Elizabeth Orr

Medicare’s device coverage process is “a system in crisis,” consultant Bruce Quinn warned at the NextGen Dx Summit. He criticized bloated NCDs, stalled advisory committees, and years-long delays, urging CMS to streamline LCDs and adopt a six-month “fast-track” model to speed innovation access.